Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive,human epidermal growth factor receptor negative,node negative early-stage breast cancer期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive,human epidermal growth factor receptor negative,node negative early-stage breast cancer

Authors:	Miguel Martín Milagros González-Rivera Serafín Morales Juan de la Haba-Rodriguez Lucía González-Cortijo Luis Manso

Affiliation:	1. Department of Medical Oncology, Hospital Gregorio Mara?ón, Madrid, Spain;2. Laboratory of Translational Oncology, Instituto de Investigación Sanitaria Gregorio Mara?ón, Madrid, Spainmmartin@geicam.org;4. Laboratory of Translational Oncology, Instituto de Investigación Sanitaria Gregorio Mara?ón, Madrid, Spain;5. Hospital Arnau de Vilanova, Lleida, Spain;6. Maimonides Institute of Biomedical Research (IMIBIC), Hospital Reina Sofía, Córdoba, Spain;7. University of Córdoba, Córdoba, Spain;8. Hospital Quirón, Madrid, Spain;9. Hospital Doce Octubre, Madrid, Spain

Abstract:

Keywords:	Adjuvant Breast cancer Genomic Intrinsic subtypes PAM50 Prosigna